Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis

✍ Scribed by Byung Woog Kang; Tae Won Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Chang Sik Yu; Jin Cheon Kim; Jong Hoon Kim; Yoon-Koo Kang; Jung Shin Lee

• Publisher: Springer US
• Year: 2008
• Tongue: English
• Weight: 188 KB
• Volume: 26
• Category: Article
• ISSN: 1357-0560
• DOI: 10.1007/s12032-008-9077-8